Volume 7 Supplement 1
Neutralizing IL-17 during re-activation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and IL-1
© BioMed Central Ltd 2005
Received: 11 January 2005
Published: 17 February 2005
Rheumatoid arthritis is characterized by an intermittent course of the disease with alternate periods of remission and relapse. T cells, and in particular the T-cell cytokine IL-17, are expected to be involved in this flare-up of arthritis.
To study the role of T-cell IL-17 in flare-up of experimental arthritis.
Antigen-induced arthritis was induced in C57Bl/6 mice by immunizing and boosting with mBSA/ complete Freund's adjuvant, and subsequent intra-articular injection of 60 μg mBSA. At week 4 of arthritis, 2 μg mBSA was injected into the arthritic joint to induce a flare-up of the smouldering inflammation. To study the role of IL-17 in this flare-up, neutralizing rabbit-anti-mouse-IL-17 antibodies (or control antibodies) were injected 2 hours prior to antigen rechallenge.
Quantitative PCR at various time points after arthritis induction showed that IL-17 mRNA expression was already upregulated at day 1, increased even more at day 2 and day 7, and clearly diminished at day 21. After antigen rechallenge, IL-17 mRNA expression rapidly increased, peaking at 4 hours with a 250-fold upregulation compared with naive mice.
Blocking IL-17 also clearly protected arthritic mice against bone erosions (Fig. 1c). Cathepsin K staining showed reduced osteoclast-like activity, and quantitative PCR showed reduced RANKL mRNA expression in the anti-IL-17-treated group. The degree of bone erosions strongly correlated with the severity of joint inflammation, suggesting that neutralizing IL-17 reduces bone erosion by suppressing joint inflammation.
Interestingly, mice treated with anti-IL-17 antibodies showed reduced protein levels of IL-1β, tumor necrosis factor alpha, and the cytokine-induced neutrophil chemoattractant KC, suggesting that IL-17 acts as an upstream mediator in destructive joint inflammation during flare-up of experimental arthritis.
These data indicate IL-17 to be an important upstream proinflammatory cytokine driving joint pathology during flare-up of experimental arthritis and suggest therapeutic benefit of neutralizing IL-17 during relapses of rheumatoid arthritis.